Targeting PP2A in cancer: Combination therapies.
Antineoplastic Agents
/ therapeutic use
Apoptosis
/ physiology
Cell Proliferation
/ physiology
DNA Repair
/ physiology
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Molecular Targeted Therapy
/ methods
Neoplasm Proteins
/ metabolism
Neoplasms
/ metabolism
Phosphoprotein Phosphatases
/ metabolism
Protein Phosphatase 2
/ genetics
Protein Subunits
/ physiology
Signal Transduction
/ physiology
Cell signaling
Protein phosphatases
Targeted therapies
Journal
Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
03
07
2018
revised:
21
08
2018
accepted:
28
08
2018
entrez:
8
11
2018
pubmed:
8
11
2018
medline:
11
9
2019
Statut:
ppublish
Résumé
The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.
Identifiants
pubmed: 30401535
pii: S0167-4889(18)30319-7
doi: 10.1016/j.bbamcr.2018.08.020
pmc: PMC6436821
mid: NIHMS1506584
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Neoplasm Proteins
0
Protein Subunits
0
Phosphoprotein Phosphatases
EC 3.1.3.16
Protein Phosphatase 2
EC 3.1.3.16
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-63Subventions
Organisme : NCI NIH HHS
ID : F30 CA224979
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181654
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.
Références
Br J Cancer. 2011 Sep 27;105(7):989-95
pubmed: 21897396
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
J Mol Cell Cardiol. 2016 Dec;101:127-133
pubmed: 27832939
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
Clin Cancer Res. 2017 Jul 1;23(13):3277-3284
pubmed: 28039265
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Mol Cancer Res. 2014 Jun;12(6):924-39
pubmed: 24667985
PLoS One. 2011;6(11):e27424
pubmed: 22087313
Blood. 2015 Jun 11;125(24):3747-55
pubmed: 25931585
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Nat Med. 2016 Mar;22(3):254-61
pubmed: 26808347
Blood. 2011 Oct 13;118(15):4150-8
pubmed: 21844565
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
Oncol Rep. 2004 Mar;11(3):655-9
pubmed: 14767517
Nat Med. 2013 Feb;19(2):232-7
pubmed: 23334847
Science. 2017 Mar 17;355(6330):1158-1163
pubmed: 28302824
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021885
Cancer Res. 2012 Dec 15;72(24):6414-24
pubmed: 23087057
Cancer Genet. 2011 Jul;204(7):375-81
pubmed: 21872824
Cancer Res. 2010 Jul 1;70(13):5438-47
pubmed: 20551067
Trends Mol Med. 2004 Jul;10(7):344-50
pubmed: 15242683
Clin Cancer Res. 2012 Apr 15;18(8):2316-25
pubmed: 22261800
Oncol Rep. 2018 Feb;39(2):565-572
pubmed: 29207165
Mol Cancer Ther. 2015 Jul;14(7):1540-1547
pubmed: 25939762
Int J Mol Med. 2014 Oct;34(4):1169-74
pubmed: 25109763
J Surg Res. 2017 Nov;219:202-213
pubmed: 29078883
Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11697-702
pubmed: 19564615
Onco Targets Ther. 2017 Dec 12;10:5907-5914
pubmed: 29276394
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1628-33
pubmed: 24425774
Clin Cancer Res. 2013 Aug 15;19(16):4422-32
pubmed: 23780887
Annu Rev Med. 2015;66:455-70
pubmed: 25341009
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19867-72
pubmed: 18056802
Neoplasia. 2009 Oct;11(10):1012-21
pubmed: 19794960
J Biol Chem. 2007 Feb 9;282(6):3766-77
pubmed: 17170118
Int J Oncol. 2013 Jun;42(6):2053-9
pubmed: 23592281
Oncogene. 2010 Jul 29;29(30):4317-29
pubmed: 20498628
Nature. 2014 Feb 6;506(7486):52-7
pubmed: 24476824
Cell Mol Life Sci. 2018 Aug;75(15):2695-2718
pubmed: 29725697
Hum Mol Genet. 2015 Sep 1;24(17):4775-9
pubmed: 25972378
Mol Cancer Ther. 2015 Jan;14(1):90-100
pubmed: 25376608
Mol Cell. 2005 Dec 9;20(5):801-9
pubmed: 16310392
Mol Oncol. 2015 Apr;9(4):889-905
pubmed: 25637283
J Clin Invest. 2013 Oct;123(10):4144-57
pubmed: 23999433
Neuroscience. 2012 Apr 5;207:288-97
pubmed: 22326202
Cell Cycle. 2015;14(13):2100-8
pubmed: 25942376
Onco Targets Ther. 2013 Jul 23;6:943-55
pubmed: 23901284
J Biol Chem. 2013 Jan 11;288(2):1032-46
pubmed: 23204520
Oncotarget. 2016 Jul 26;7(30):47465-47478
pubmed: 27329844
Int J Biochem Cell Biol. 2018 Mar;96:182-193
pubmed: 29107183
Lancet Oncol. 2013 May;14(6):e229-38
pubmed: 23639323
Cancer Lett. 2014 Jun 1;347(2):204-11
pubmed: 24576621
Oncotarget. 2016 Sep 20;7(38):61544-61561
pubmed: 27557495
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Bioorg Med Chem. 2015 Oct 1;23(19):6528-34
pubmed: 26372073
J Biol Chem. 2002 Jun 14;277(24):21453-7
pubmed: 11967257
Cancer Sci. 2010 May;101(5):1226-33
pubmed: 20331621
Clin Cancer Res. 2015 Jan 1;21(1):113-22
pubmed: 25009295
Nature. 2014 Jun 19;510(7505):407-411
pubmed: 24919154
Mol Cancer Ther. 2009 Jan;8(1):135-40
pubmed: 19139122
Tumour Biol. 2016 Jun;37(6):7277-86
pubmed: 26666823
Nat Cell Biol. 2004 Apr;6(4):308-18
pubmed: 15048125
Nat Commun. 2018 May 29;9(1):2126
pubmed: 29844427
Clin Cancer Res. 2016 May 15;22(10):2534-44
pubmed: 26733615
Sci Transl Med. 2018 Feb 7;10(427):
pubmed: 29437150
Biochem Pharmacol. 2014 Feb 1;87(3):399-409
pubmed: 24231507
Clin Cancer Res. 2015 Jan 15;21(2):347-56
pubmed: 25388166
Oncotarget. 2018 May 1;9(33):23003-23017
pubmed: 29796168
J Clin Invest. 2015 Aug 3;125(8):3051-62
pubmed: 26168268
Clin Cancer Res. 2014 Apr 15;20(8):2092-103
pubmed: 24436473
Endocrinology. 2014 Feb;155(2):380-91
pubmed: 24265448
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Ann Oncol. 2017 Feb 1;28(2):354-361
pubmed: 27998964
Int J Biochem Cell Biol. 2018 Mar;96:98-134
pubmed: 29031806
Front Genet. 2014 Nov 07;5:382
pubmed: 25426138
FEBS J. 2016 Mar;283(6):1004-24
pubmed: 26507691
Mol Cancer Ther. 2016 Oct;15(10):2465-2474
pubmed: 27507852
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
FEBS Lett. 2011 Mar 9;585(5):755-60
pubmed: 21241697
Oncotarget. 2014 Sep 15;5(17):7512-24
pubmed: 25245035
J Clin Oncol. 2012 Nov 10;30(32):3967-75
pubmed: 23045588
Oncotarget. 2016 Jan 5;7(1):638-55
pubmed: 26575017
Oncogene. 2010 Jul 8;29(27):3933-41
pubmed: 20473327
Hepatology. 2011 Jun;53(6):1943-58
pubmed: 21391227
Neuro Oncol. 2018 May 18;20(6):799-809
pubmed: 29294092
Cancer Cell. 2005 Nov;8(5):355-68
pubmed: 16286244
Invest New Drugs. 2015 Jun;33(3):720-8
pubmed: 25637165
J Clin Invest. 2014 Feb;124(2):644-55
pubmed: 24401270
Oncologist. 2013;18(10):1091-2
pubmed: 24072218
Hum Pathol. 2018 Feb;72:199-201
pubmed: 29247663
J Biol Chem. 2017 Feb 24;292(8):3420-3432
pubmed: 28069811
J Neuropathol Exp Neurol. 2004 Apr;63(4):287-301
pubmed: 15099019
Mol Biosyst. 2014 Feb;10(2):240-50
pubmed: 24253262
Hematology Am Soc Hematol Educ Program. 2009;:353-61
pubmed: 20008221
Cancer Lett. 2018 Feb 28;415:217-226
pubmed: 29199006
J Hematol Oncol. 2011 Apr 01;4:13
pubmed: 21453545
Tumour Biol. 2016 Sep;37(9):11691-11700
pubmed: 27444275
Cancer Res. 2016 Oct 1;76(19):5719-5731
pubmed: 27485451
J Clin Oncol. 2016 Oct 20;34(30):3638-3647
pubmed: 27480147
Science. 2002 Apr 12;296(5566):346-9
pubmed: 11923495
J Biol Chem. 2010 Jun 4;285(23):17648-61
pubmed: 20356833
Nat Immunol. 2016 May;17(5):556-64
pubmed: 26974206
Lancet Haematol. 2016 Apr;3(4):e186-95
pubmed: 27063977
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Mol Cancer Ther. 2014 Apr;13(4):938-47
pubmed: 24448818
J Neurosurg. 2010 Aug;113(2):225-33
pubmed: 20001590
Biomaterials. 2010 Dec;31(36):9535-43
pubmed: 20875681
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972
J Neurosci. 2011 May 11;31(19):6963-71
pubmed: 21562258
J Clin Oncol. 2011 Jan 1;29(1):4-7
pubmed: 21115867
J Clin Invest. 2017 Jun 1;127(6):2081-2090
pubmed: 28504649
J Clin Invest. 2007 Sep;117(9):2408-21
pubmed: 17717597
J Biol Chem. 2014 Dec 5;289(49):33862-73
pubmed: 25320082
Biochem Pharmacol. 2012 Sep 1;84(5):591-7
pubmed: 22583922
Cancer Res. 2005 Sep 15;65(18):8183-92
pubmed: 16166293
Oncotarget. 2015 Feb 28;6(6):4299-314
pubmed: 25726524
Oncotarget. 2016 Mar 15;7(11):12447-63
pubmed: 26799670
Cancer Treat Rev. 2018 Jun;67:34-44
pubmed: 29753961